Book contents
- Dispatches from the Land of Alzheimer’s
- Reviews
- Dispatches from the Land of Alzheimer’s
- Copyright page
- Dedication
- Lost in Thought
- Contents
- Acknowledgments
- Prologue
- 1 Physician Heal Thyself
- 2 Evaluating New Advances in Alzheimer’s Research
- 3 Alzheimer’s Dementia or Alzheimer’s Disease
- 4 The First Patient with Alzheimer’s Disease
- 5 Kidnapped in Kinshasa
- 6 Smell, Disgust, and Alzheimer’s
- 7 Apolipoprotein-4 (APOE-4)
- 8 Lost in the Fog of Alzheimer’s
- 9 My Father’s “Stuff”
- 10 Face Blindness during a Pandemic
- 11 Biomarkers for Alzheimer’s Disease
- 12 Olfactory Impairment in Covid-19 and Alzheimer’s
- 13 Alzheimer’s Disease and Work
- 14 Crossword Controversies
- 15 Can Loneliness Increase Risk for Dementia?
- 16 Excessive Laxative Use and Dementia
- 17 Dog Dementia (Canine Cognitive Dysfunction)
- 18 The Possible Role of Brain Inflammation in Alzheimer’s Disease May Be More Significant in APOE-4 Carriers
- 19 Surprisingly Good News about the Acetylcholinesterase Inhibitors (Donepezil, Rivastigmine, and Galantamine)
- 20 More about the Importance of Exercise
- 21 Rolling on the River
- 22 The MIND Diet Revisited
- 23 My Photographs, Then and Now
- 24 Does Cataract Surgery Really Decrease the Risk of Dementia?
- 25 Hearing Loss, Aphasia, and Dementia
- 26 To Sleep, Perchance to Dream
- 27 The Amyloid Hypothesis Is Not Dead, but It May Be Gasping for Breath
- 28 Could Lecanemab Offer a Ray of Hope?
- 29 A Fatal Case of Multiple Brain Hemorrhages Associated with Lecanemab
- 30 Cerebral Amyloid Angiopathy (CAA)
- 31 Hitting the Sweet Spot in the Spectrum of Alzheimer’s Disease for Future Trials of Anti-Amyloid Medications
- 32 Disappointing Results of Two Human Trials of Monoclonal Antibodies in Parkinson’s Disease
- 33 Repurposing Old Drugs for Alzheimer’s Treatment
- 34 Writing While Impaired
- 35 Spreading the Word
- 36 Saying Goodbye to Lizzie G
- 37 Amyloid and Tau PET Scans of My Brain
- 38 Running on a Field of Dreams
- 39 Living in the Moment with Alzheimer’s
- Index
- Plate Section (PDF Only)
- References
32 - Disappointing Results of Two Human Trials of Monoclonal Antibodies in Parkinson’s Disease
Published online by Cambridge University Press: 19 January 2024
Book contents
- Dispatches from the Land of Alzheimer’s
- Reviews
- Dispatches from the Land of Alzheimer’s
- Copyright page
- Dedication
- Lost in Thought
- Contents
- Acknowledgments
- Prologue
- 1 Physician Heal Thyself
- 2 Evaluating New Advances in Alzheimer’s Research
- 3 Alzheimer’s Dementia or Alzheimer’s Disease
- 4 The First Patient with Alzheimer’s Disease
- 5 Kidnapped in Kinshasa
- 6 Smell, Disgust, and Alzheimer’s
- 7 Apolipoprotein-4 (APOE-4)
- 8 Lost in the Fog of Alzheimer’s
- 9 My Father’s “Stuff”
- 10 Face Blindness during a Pandemic
- 11 Biomarkers for Alzheimer’s Disease
- 12 Olfactory Impairment in Covid-19 and Alzheimer’s
- 13 Alzheimer’s Disease and Work
- 14 Crossword Controversies
- 15 Can Loneliness Increase Risk for Dementia?
- 16 Excessive Laxative Use and Dementia
- 17 Dog Dementia (Canine Cognitive Dysfunction)
- 18 The Possible Role of Brain Inflammation in Alzheimer’s Disease May Be More Significant in APOE-4 Carriers
- 19 Surprisingly Good News about the Acetylcholinesterase Inhibitors (Donepezil, Rivastigmine, and Galantamine)
- 20 More about the Importance of Exercise
- 21 Rolling on the River
- 22 The MIND Diet Revisited
- 23 My Photographs, Then and Now
- 24 Does Cataract Surgery Really Decrease the Risk of Dementia?
- 25 Hearing Loss, Aphasia, and Dementia
- 26 To Sleep, Perchance to Dream
- 27 The Amyloid Hypothesis Is Not Dead, but It May Be Gasping for Breath
- 28 Could Lecanemab Offer a Ray of Hope?
- 29 A Fatal Case of Multiple Brain Hemorrhages Associated with Lecanemab
- 30 Cerebral Amyloid Angiopathy (CAA)
- 31 Hitting the Sweet Spot in the Spectrum of Alzheimer’s Disease for Future Trials of Anti-Amyloid Medications
- 32 Disappointing Results of Two Human Trials of Monoclonal Antibodies in Parkinson’s Disease
- 33 Repurposing Old Drugs for Alzheimer’s Treatment
- 34 Writing While Impaired
- 35 Spreading the Word
- 36 Saying Goodbye to Lizzie G
- 37 Amyloid and Tau PET Scans of My Brain
- 38 Running on a Field of Dreams
- 39 Living in the Moment with Alzheimer’s
- Index
- Plate Section (PDF Only)
- References
Summary
Like Alzheimer’s disease, Parkinson’s disease is a progressive, neurodegenerative disorder that involves deposits of an abnormal protein in the brain. In Alzheimer’s disease, these abnormal proteins are extracellular beta-amyloid and intraneuronal, hyperphosphorylated tau. In Parkinson’s disease, the neuropathological findings are protein deposits of aggregated alpha-synuclein found primarily within neurons in a part of the brainstem called the substantia nigra but in other locations as well. These clumps of alpha-synuclein are called Lewy bodies.
In the August 4, 2022 issue of the New England Journal of Medicine, we have reports of two phase 2 human trials of monoclonal antibodies directed at alpha-synuclein in subjects with early-stage Parkinson’s disease, prasinezumab and cinpanemab.
- Type
- Chapter
- Information
- Dispatches from the Land of Alzheimer's , pp. 130 - 133Publisher: Cambridge University PressPrint publication year: 2024
References
Fields, CR, Bengoa-Vergniory, N, Wade-Martins, R. Targeting alpha-synuclein as a therapy for Parkinson’s disease. Front Mol Neurosci 2019; 12: 299. https://doi.org/10.3389/fnmol.2019.00299 (open access).CrossRefGoogle ScholarPubMed
van Dyck, CH, Swanson, CJ, Aisen, P, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med 2023; 388: 9–21. https://doi.org/10.1056/NEJMoa2212948.CrossRefGoogle ScholarPubMed
Pagano, G, Taylor, KI, Anzures-Cabrera, J, et al. Trial of prasinezumab in early-stage Parkinson’s disease. N Engl J Med 2022; 387: 421–432. https://doi.org/10.1056/NEJMoa2202867.CrossRefGoogle ScholarPubMed
Lang, AE, Siderowf, AD, Macklin, EA, et al. Trial of cinpanemab in early Parkinson’s disease. N Engl J Med 2022; 387: 408–420. https://doi.org/10.1056/NEJMoa2203395.CrossRefGoogle ScholarPubMed
Espay, AJ, Okun, MS. Abandoning the proteinopathy paradigm in Parkinson’s disease. JAMA Neurol 2023; 80: 123–124. https://doi.org/10.1001/jamaneurol.2022.4193.CrossRefGoogle Scholar